Evidence supporting the use of: N-acetyl-cysteine (NAC)
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

N-acetyl-cysteine (NAC) is used to support/treat Parkinson’s Disease (PD) primarily based on scientific rationale rather than tradition. NAC is a precursor to glutathione, a major endogenous antioxidant, and is thought to cross the blood-brain barrier, potentially increasing brain glutathione levels. Oxidative stress and glutathione depletion are well-documented features in the pathology of PD, and this underpins NAC’s theoretical benefits.

Several preclinical studies in animal models of PD have shown that NAC can reduce oxidative damage and protect dopaminergic neurons. Human evidence is limited but growing: a small open-label pilot study published in 2016 (Monti et al., PLOS ONE) enrolled PD patients who received intravenous plus oral NAC. The results showed increased dopamine transporter binding on SPECT imaging and modest improvements in clinical symptoms, suggesting a potential neuroprotective effect. However, these findings are preliminary, and the study had significant limitations including its small sample size, lack of blinding, and short duration.

As of now, there are no large-scale, randomized, placebo-controlled trials definitively demonstrating clinical benefit of NAC in PD. Nevertheless, the mechanistic rationale and early clinical signals justify further research. The overall evidence is rated as 2 out of 5, indicating weak but biologically plausible support. NAC is not part of standard PD treatment, but may be used as an adjunct in research or integrative settings.

More about n-acetyl-cysteine (NAC)
More about Parkinson's Disease